Novel Photodynamic Therapy Does Not Prevent New Skin Cancers—Randomized Controlled Trial

Dixon, Andrew; Anderson, Stuart; Mazzurco, Jason D.; Steinman, Howard K.

doi:10.1111/dsu.12462

Cited by 11 publications

(15 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ALA-PDT, which combines a photosensitizer with a source light and oxygen can specifically destroy the lesion, thereby killing only tumor cells (14). As a precursor of hemoglobin, 5-ALA is a recently developed second-generation photosensitizer.…”

Section: Discussionmentioning

confidence: 99%

Surgery combined with local 5-aminolevulinic acid-photodynamic therapy on skin cancer and its effect on the expression of cyclophilin A, cyclophilin B and CD147

Guo¹,

Han²

2017

Oncology Letters

View full text Add to dashboard Cite

The study evaluated an approach to treat skin cancer using surgery combined with local 5-aminolevulinic acid-photodynamic therapy (ALA-PDT). Seventy-six patients with skin cancer who were admitted to the Liaocheng People's Hospital from May 2014 to April 2015 were randomly divided into a control and an observation group (38 cases in each). The patients in the control group were treated with ALA-PDT alone. Those in the observation group were first subjected to surgical treatment, and then treated with ALA-PDT. The treatment efficacies of the two groups were compared. The expression of cancer markers CyPA, CyPB and CD147 were detected by immunohistochemical methods before and after the treatment. Our results showed the average healing time of the wounds of patients in the observation group was shorter, the number of treatments needed was less, the efficacy rate and the lesion appearance satisfaction were significantly higher, and the recurrence rate at 12 months after treatment and the incidence of adverse reactions were both significantly lower. Additionally, the levels of CyPA, CyPB and CD147 were reduced to a significantly higher degree after treatment in the observation group. No difference was found in the recurrence rate between the two groups at 6 months after treatment. We conclude that surgery combined with ALA-PDT is a safe and reliable treatment method, which can increase the survival rate while improving the recovery rate and appearance satisfaction in patients with skin cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Surgery combined with local 5-aminolevulinic acid-photodynamic therapy on skin cancer and its effect on the expression of cyclophilin A, cyclophilin B and CD147

Guo¹,

Han²

2017

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…Inclusion and exclusion criteria were listed in all the trials. Sixteen trials recruited patients with a history of KC 8–23 ; six of them also included patients with AK on the face 8,9,13,18,19,23 . Two trials included only patients with AK 24 .…”

Section: Resultsmentioning

confidence: 99%

“…The trials interventions were oral nicotinamide, 10,24 oral selenium, 11 photodynamic therapy (PDT) with 5‐aminolevulinate (ALA), 12,18 oral celecoxib, 13,25 oral beta carotene, 14 carbon dioxide laser, 9 30% trichloroacetic acid peel, 9 5% fluorouracil cream, 9,23 low‐fat diet, 15 oral acitretin, 16 oral retinol, 8,17 oral isotretinoin 10 mg, 21 tretinoin 0.1% cream, 22 sunscreen, 19 PDT with methyl aminolevulinate (MAL), 20 imiquimod 5% cream, 20 oral vismodegib, 26,28 tazarotene 0.1% cream, 27 and T4N5 liposome lotion (Table 2). 29 …”

Section: Resultsmentioning

confidence: 99%

Quality of clinical trials for the prevention of keratinocyte cancer

et al. 2020

View full text Add to dashboard Cite

Keratinocyte cancer (KC) is the most common form of cancer in humans. To our knowledge, no previous publications assessing the methodological quality of clinical trials for the prevention of KC have been recently published. We aim to assess the methodological quality of clinical trials focused on the prevention of KC in high-risk groups not receiving immunosuppressive therapy (NRIT) and propose solutions to improve the design of future trials. We searched clinical trials in which the main outcome was the prevention of KC in high-risk NRIT groups using the strategy published in the International Prospective Register of Systematic Reviews (PROSPERO registry), CRD42016045981. Consolidated Standards of Reporting Trials (CONSORT) criteria and the Cochrane Collaboration risk of bias tool were used to assess methodological quality. We analyzed 23 clinical trials. We found a high risk of attrition and reporting bias in 86.9% and 60.9% of the trials, respectively. Regarding the CONSORT criteria, in at least 40% of the trials, the authors omitted the following information: a description of the trial design, the number of losses and exclusions after randomization, the results of subgroup and adjusted analysis, the estimated effect size and the precision of primary and secondary outcomes. Methodological quality was improved in the recently published clinical trials compared to those published before the CONSORT criteria development. All clinical trials should report in detail the information used to assess potential risks of bias.

show abstract

“…After manuscript review, two were excluded for being duplicates and 27 were excluded for not being RCTs. This left 181 articles in 27 journals to be included in the review . Of these, 137 studies had parallel‐armed control groups, 42 had placebo control groups, one was a cross‐over design and one used no treatment as the control group.…”

Section: Resultsmentioning

confidence: 99%

Statistical reporting in randomized controlled trials from the dermatology literature: a review of 44 dermatology journals

McClean

Silverberg

2015

Br J Dermatol

View full text Add to dashboard Cite

show abstract

Novel Photodynamic Therapy Does Not Prevent New Skin Cancers—Randomized Controlled Trial

Abstract: Novel ALA made no difference in the likelihood of new malignancies developing. The risks without benefit of this novel ALA are troubling. Lack of efficacy and safety of novel ALA cannot be extrapolated to other PDT products.

Cited by 11 publications

References 21 publications

Surgery combined with local 5-aminolevulinic acid-photodynamic therapy on skin cancer and its effect on the expression of cyclophilin A, cyclophilin B and CD147

Surgery combined with local 5-aminolevulinic acid-photodynamic therapy on skin cancer and its effect on the expression of cyclophilin A, cyclophilin B and CD147

Quality of clinical trials for the prevention of keratinocyte cancer

Statistical reporting in randomized controlled trials from the dermatology literature: a review of 44 dermatology journals

Contact Info

Product

Resources

About